Evicenter
P&T meetings

LB-102

Schizophrenia

Regulatory submission
Not announced
Launch
Not announced
Last updated
345 sources

Product information and disease descriptionProduct descriptionProduct information

Generic, brand name and therapeutic class of product

3 evidence topics · 5 sources

Manufacturer: LB Pharmaceuticals Inc

“LB Pharmaceuticals Inc.” (opens the source at this quote in a new tab)

“We currently own global rights to LB-102 and intend to retain commercialization rights in the United States.” (opens the source at this quote in a new tab)

Product names: development code and chemical names
FieldQuoted record
Preferred substance name“LB-102”
Unique ingredient identifier“N81WKW91XF”
Formula“C18H29N3O4S”
Synonym“N'-METHYL AMISULPRIDE”
Systematic name“4-(METHYLAMINO)-N-(((2RS)-1-ETHYLPYRROLIDIN-2-YL)METHYL)-5-(ETHYLSULFONYL)-2-METHOXYBENZAMIDE.”
Chemical Abstracts Service registry number“2227154-23-4”

“A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study of LB-102 N-Methyl amisulpride) in healthy volunteers.” (opens the source at this quote in a new tab)

“In addition, our lead product candidate, LB-102, is an N-methylated version of amisulpride, a drug already approved in certain parts of Europe for the treatment of schizophrenia, predominantly negative symptoms of schizophrenia and dysthymia.” (opens the source at this quote in a new tab)

International nonproprietary name, United States adopted name, and brand name

No evidence found.

Therapeutic class

“LB-102 is a novel, patent-protected benzamide antipsychotic drug that we designed to improve upon the clinical profile of amisulpride and address its limitations.” (opens the source at this quote in a new tab)

“Our lead product candidate, LB‑102, is a Phase 3 oral small molecule in development for the treatment of schizophrenia.” (opens the source at this quote in a new tab)

“LB-102 is a potent and selective antagonist of D2, D3, and 5-HT7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders.” (opens the source at this quote in a new tab)